Compare FLXS & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLXS | MGNX |
|---|---|---|
| Founded | 2001 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 257.1M | 220.6M |
| IPO Year | 1995 | 2013 |
| Metric | FLXS | MGNX |
|---|---|---|
| Price | $65.26 | $4.12 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $54.00 | $5.00 |
| AVG Volume (30 Days) | 38.6K | ★ 609.3K |
| Earning Date | 04-20-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.41% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 3.63 | N/A |
| Revenue | ★ $441,073,000.00 | $149,500,000.00 |
| Revenue This Year | $4.51 | N/A |
| Revenue Next Year | $4.89 | $3.19 |
| P/E Ratio | $17.44 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $32.65 | $1.19 |
| 52 Week High | $65.03 | $4.64 |
| Indicator | FLXS | MGNX |
|---|---|---|
| Relative Strength Index (RSI) | 70.91 | 55.21 |
| Support Level | $52.27 | $1.49 |
| Resistance Level | N/A | $4.55 |
| Average True Range (ATR) | 2.49 | 0.25 |
| MACD | 0.50 | -0.04 |
| Stochastic Oscillator | 95.81 | 47.29 |
Flexsteel Industries Inc is a United States-based company that manufactures, imports, and markets residential upholstered wooden furniture products. Its product offerings include sofas, loveseats, chairs, rockers, desks, tables, convertible bedding units, and bedroom furniture. The company's products are intended for use in home, office, hotel, healthcare, and other contract applications. A featured component in the company's upholstered furniture is the durable Blue Steel Spring. It operates in the business segment of Furniture products. The company's furniture products business involves the distribution of manufactured and imported products for residential markets.
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.